Research Article
Prognostic Significance of Serum Free Light Chains in Chronic Lymphocytic Leukemia
Table 1
Patients’ characteristics.
| | Number of patients | 143 | | Median age | 63 years (range 37–87) | | Sex male/female | 64/79 (45%/55%) | | Rai stage | | | 0 | 64 (45%) | | I | 46 (32%) | | II | 14 (10%) | | III | 14 (10%) | | IV | 5 (3%) | | Binet stage | | | A | 89 (62%) | | B | 31 (22%) | | C | 23 (16%) | | Lymphadenopathy | 79 (55%) | | Splenomegaly | 23 (16%) | | LDH (>normal upper limit) | 20 (14%) | | Hemoglobin, g/dL, median (range) | 13,5 (4–17,8) | | White blood cell counts, ×109/L, median (range) | 21,600 (7–600) | | Lymphocytes absolute value, ×109/L, median (range) | 14 (5–580) | | Beta-2-microglobulin, mg/L median (range)* | 2,5 (1,18–8,8) | | CD38 expression > 20% | 14 (10%) | | FISH and IGVH status** | 34 (24%) | | Symptomatic | 18 (12,5%) | | Median followup | 32 months (range 4–228) |
|
|
*Evaluated in 69 patients.
**The percentage of patients that were positive is too small to be evaluated.
|
